



US008835382B2

(12) **United States Patent**  
**O'Connor et al.**

(10) **Patent No.:** **US 8,835,382 B2**  
(45) **Date of Patent:** **Sep. 16, 2014**

- (54) **LIPOPEPTIDE COMPOSITIONS AND RELATED METHODS**
- (75) Inventors: **Sandra O'Connor**, Hudson, NH (US);  
**Sophie Sun**, Lexington, MA (US);  
**Gauri Naik**, Cambridge, MA (US)
- (73) Assignee: **Cubist Pharmaceuticals, Inc.**,  
Lexington, MA (US)
- (\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

5,955,509	A	9/1999	Webber et al.
6,194,383	B1	2/2001	Hammann et al.
6,468,967	B1	10/2002	Oleson et al.
6,696,412	B1	2/2004	Kelleher et al.
6,716,962	B2	4/2004	Borders et al.
6,852,689	B2	2/2005	Oleson et al.
RE39,071	E	4/2006	Baker et al.
7,138,487	B2	11/2006	Borders et al.
7,279,597	B1	10/2007	Leone-Bay et al.
8,058,238	B2	11/2011	Kelleher et al.
8,129,342	B2	3/2012	Kelleher
8,309,061	B2	11/2012	Chaudry
8,431,539	B2	4/2013	Palepu et al.
2002/0111311	A1	8/2002	Govardhan et al.
2002/0132762	A1	9/2002	Borders
2003/0045484	A1	3/2003	Keith
2003/0045678	A1	3/2003	Keith
2004/0067878	A1	4/2004	Hill
2004/0077601	A1	4/2004	Adams
2004/0242467	A1	12/2004	Borders
2005/0009747	A1	1/2005	Kelleher
2005/0027113	A1	2/2005	Miao et al.
2005/0196418	A1	9/2005	Yu
2006/0014674	A1	1/2006	Keith
2006/0018933	A1	1/2006	Vaya
2006/0018934	A1	1/2006	Vaya
2006/0024365	A1	2/2006	Vaya
2006/0264513	A1	11/2006	Leone-Bay et al.
2006/0269485	A1	11/2006	Friedman
2007/0116729	A1	5/2007	Palepu

- (21) Appl. No.: **13/511,246**
- (22) PCT Filed: **Nov. 23, 2010**
- (86) PCT No.: **PCT/US2010/057910**  
§ 371 (c)(1),  
(2), (4) Date: **Jul. 10, 2012**
- (87) PCT Pub. No.: **WO2011/063419**  
PCT Pub. Date: **May 26, 2011**
- (65) **Prior Publication Data**  
US 2012/0270772 A1 Oct. 25, 2012

**Related U.S. Application Data**

- (60) Provisional application No. 61/263,784, filed on Nov. 23, 2009.
- (51) **Int. Cl.**  
**A61K 38/12** (2006.01)  
**A61K 38/10** (2006.01)  
**A61P 31/04** (2006.01)  
**C07K 11/02** (2006.01)  
**A61K 9/00** (2006.01)
- (52) **U.S. Cl.**  
CPC ..... **A61K 38/12** (2013.01); **A61K 38/10** (2013.01); **A61K 9/00** (2013.01); **C07K 11/02** (2013.01)  
USPC ..... **514/2.4**; 514/2.9; 514/3.1; 514/21.1; 514/21.5
- (58) **Field of Classification Search**  
CPC ..... **A61K 38/10**; **A61K 38/12**; **A61K 9/00**; **C07K 11/02**  
See application file for complete search history.

- (56) **References Cited**  
U.S. PATENT DOCUMENTS

4,331,594	A	5/1982	Hamill et al.
4,439,425	A	3/1984	Tarcsay et al.
4,482,487	A	11/1984	Abbott et al.
4,537,717	A	8/1985	Abbott et al.
4,874,843	A	10/1989	Baker et al.
4,882,164	A	11/1989	Ferro et al.
5,271,935	A	12/1993	Franco et al.
5,336,756	A	8/1994	Schwartz et al.
5,387,670	A	2/1995	Roy et al.
5,629,288	A	5/1997	Lattrell et al.
5,912,226	A	6/1999	Baker et al.

(Continued)

**FOREIGN PATENT DOCUMENTS**

CN	1592753	A	3/2005	
CN	1616083	A	* 5/2005	..... A61K 38/12

(Continued)

**OTHER PUBLICATIONS**

pH-water quality, from <http://extension.usu.edu/waterquality/htm/whats-in-your-water/ph>, pp. 1-2, accessed Jul. 23, 2013.\*

Smales et al, Therapeutic proteins, methods and protocols, Humana press, 2005, pp. 287-292.\*

Wang, Lyophilization and development of solid protein pharmaceuticals, International Journal of Pharmaceutics, 2000, 203, pp. 1-60.\*

Machien translation of CN 1616083 A, pp. 1-9, publication date May 18, 2005.\*

Miao et al., "Daptomycin biosynthesis in *Streptomyces roseosporus*: cloning and analysis of the gene cluster and revision of peptide stereochemistry," Microbiology 2005, vol. 151 (5), 1507-23.

Debono, et al., "A21978C, A Complex of New Acidic Peptide Antibiotics: Isolation, Chemistry, and Mass Spectral Structure Elucidation," The Journal of Antibiotics 1987, vol. XL (6), p. 761-77.

(Continued)

*Primary Examiner* — Julie Ha  
*Assistant Examiner* — Li Ni Komatsu  
(74) *Attorney, Agent, or Firm* — Lathrop & Gage LLP; Brian C. Trinqu; Gang Wang

(57) **ABSTRACT**

The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.

**18 Claims, 22 Drawing Sheets**

(56)

## References Cited

## U.S. PATENT DOCUMENTS

2007/0128694 A1 6/2007 Baltz et al.  
 2007/0191280 A1 8/2007 Kelleher  
 2008/0220441 A1 9/2008 Birnbaum  
 2009/0197799 A1 8/2009 Keith  
 2010/0041589 A2 2/2010 Keith et al.  
 2011/0124551 A1 5/2011 Palepu et al.  
 2011/0172167 A1 7/2011 Palepu et al.  
 2011/0207658 A1 8/2011 Kelleher  
 2012/0149062 A1 6/2012 Kelleher et al.  
 2012/0270772 A1 10/2012 O'Connor

## FOREIGN PATENT DOCUMENTS

CN 101330905 A 12/2008  
 EP 0178152 4/1986  
 EP 0294990 12/1988  
 EP 0386951 A2 3/1989  
 EP 0511866 11/1992  
 EP 0521408 1/1993  
 EP 0629636 12/1994  
 EP 1252179 10/2002  
 JP 64047388 2/1989  
 JP 04224197 8/1992  
 JP 05239090 9/1993  
 JP 05271284 10/1993  
 WO WO9321207 10/1993  
 WO WO9927954 6/1999  
 WO WO 9927957 6/1999  
 WO WO 9940113 8/1999  
 WO WO9943700 9/1999  
 WO WO 0018419 4/2000  
 WO WO01/44274 A1 6/2001  
 WO WO 01/53330 7/2001  
 WO WO01/53330 A2 7/2001  
 WO WO0153330 7/2001  
 WO WO02/055537 A1 7/2002  
 WO WO02/056829 A2 7/2002  
 WO WO02/059145 A1 8/2002  
 WO WO02059145 8/2002  
 WO WO02/096936 A2 12/2002  
 WO WO02096936 12/2002  
 WO WO2004/004658 A2 1/2004  
 WO WO2006/084174 A2 8/2006  
 WO WO2006/084174 A3 8/2006  
 WO WO2007/061529 A1 5/2007  
 WO WO2007/099396 A2 9/2007  
 WO WO2007/099396 A3 9/2007  
 WO WO2008/127291 A2 10/2008  
 WO WO2008/127291 A3 10/2008  
 WO WO2009144739 A1 12/2009  
 WO WO2011/019839 A2 2/2011  
 WO WO2011/035108 A1 3/2011  
 WO WO2011/062676 A1 5/2011  
 WO WO2011/063419 A2 5/2011  
 WO WO2012/061360 A2 5/2012  
 WO WO2012/088441 A1 6/2012  
 WO WO2012/112319 A1 8/2012

## OTHER PUBLICATIONS

Lodish et al., *Molecular Cell Biology* (ed. By J. Darnell, H. Lodish, and D. Baltimore, Scientific American Books, Inc., New York: 1986), Chapter 3, p. 53.  
 Woodworth et al., "Single-Dose Pharmacokinetics and Antibacterial Activity of Daptomycin, a New Lipopeptide Antibiotic, in Healthy Volunteers," *Antimicrobial Agent and Chemotherapy* 1992, vol. 36, p. 318-25.  
 McKindley et al., "Drug Use in the Critically III Patient with Renal Dysfunction-Application of the DREM System," *Infectious Diseases in Critical Care Medicine Biotechnology of Antibiotics* (ed. B.A. Cunha, New York: Marcel Dekker, Inc., 1998) Chapter 41, pp. 781-801.  
 Tally et al., Daptomycin: a novel agent for Gram-positive infections; *Expert Opinion. On Investigational Drugs*; 1999, vol. 8, pp. 1223-1238.

Janson et al., *Protein Purification: Principles, High Resolution Methods, and Applications*; Ch. 1: Introduction to Protein Purification; John Wiley & Sons, Inc., 1998; pp. 3-48, p. 80, and pp. 125-126.  
 Lin et al., "Recovery and Purification of the Lipopeptide Biosurfactant of *Bacillus subtilis* by Ultrafiltration," *Biotechnology Techniques*, 1997, vol. 11, p. 413-16.  
 Shaw, D.J., "Liquid-Gas and Liquid-Liquid Interfaces," *Introduction to Colloid and Surface Chemistry*, Butterworth-Heinemann Ltd., 1989, pp. 49-90.  
 Kirsch, et al., "Kinetics of the Aspartyl Transpeptidation of Daptomycin, a Novel Lipopeptide Antibiotic," *Pharmaceutical Research*; 1989, vol. 6, p. 387-93.  
 Remington: *The Science and Practice of Pharmacy*, (19th edition, Mack Publishing Company, 1985), pp. 539-551, 1529-1530, 1549-1550, and 1558.  
 Sexton D. et al., "The Use of Daptomycin, a Lipopeptide Antibiotic, in the Treatment of Gram Positive Infections in Man," *Interscience Conference on Antimicrobial Agents and Chemotherapy* 1988, Abstract No. 932.  
 Selwyn, et al.; *Infections (Excluding AIDS) of Injection Drug Users*; Harrison's Principles of Internal Medicine; Fauci, et al. eds., 14th ed., McGraw-Hill, 1998, pp. 831-832, and 847.  
 Lee et al., *Program and Abstracts of the ICAAC 1991*, Abstract No. 865.  
 Rotschafer et al., "Therapeutic Update on Glycopeptide and Lipopeptide Antibiotics," *Pharmacotherapy* 1988, vol. 8, 211-19.  
 Mutschler et al., *Drug Actions: Basic Principles and Therapeutic Aspects*; Ch. 2: Pharmacokinetics; Medpharm Scientific Publishers, Stuttgart, Germany (1995); p. 5, 47 pages.  
 Freeman et al., *Once-daily Dosing of Aminoglycosides: Review and Recommendations for Clinical Practice*; *J. Antimicrob. Chemother.* 1997, vol. 39, p. 677-86.  
 Ebert et al., *Pharmacodynamics Properties of Antibiotics: Application to Drug Monitoring and Dosage Regimen Design; Infection Control and Hospital Epidemiology*; 1990, 11(6), pp. 319-326.  
 Barclay et al., *What is the Evidence for Once-Daily Aminoglycoside Therapy*; *Clin. Pharmacokinetics*. 1994, 27(i), pp. 32-48.  
 Baltz, "Lipopeptide Antibiotics Produced by *Streptomyces roseosporus* and *Streptomyces fradiae*," *Biotechnology of Antibiotics* 1997, 2d ed.; pp. 415-435.  
 Craig, "Once-daily versus multiple-daily dosing of aminoglycosides," *J Chemother.*; 1995, vol. 7 (Suppl 2), pp. 47-52.  
 Schnellmann et al.; *Cassarett and Douls Toxicology: The Basic Science of Poisons*; Chapter 14: Toxic Responses of the Kidney; (5th ed.) (1996), pp. 491-514.  
 Benoit et al., "Destruction and regeneration of skeletal muscle after treatment with a local anesthetic, bupivacaine (Marcaine®)," *J Anat.* 1970, vol. 107, pp. 547-556.  
 Cubist Pharmaceuticals, *Press Release*, Feb. 5, 2008, Lexington, MA.  
 U.S. Appl. No. 07/060,148, filed Jun. 10, 1987; *File History*; Abandoned.  
 Akins et al., *In Vitro Activities of Daptomycin, Arbekacin, Vancomycin, and Gentamicin Alone and/or in Combination against Glycopeptide Intermediate-Resistant *Staphylococcus aureus* in an Infection Model*; *Antimicrobial Agents and Chemotherapy*; 2000, vol. 44, pp. 1925-1929.  
 Akins et al.; *Bactericidal Activities of Two Daptomycin Regimens against Clinical Strains Glycopeptide Intermediate-Resistant *Staphylococcus aureus*, Vancomycin-Resistant *Enterococcus faecium*, and Methicillin-Resistant *Staphylococcus aureus* Isolates in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations*; *Antimicrobial Agents and Chemotherapy*; 2001, vol. 45, pp. 454-459.  
 Arbeit et al., *The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections*; *Clinical Infectious Diseases*; 2004, vol. 38, pp. 1673-1681.  
 Auwera et al., *Ex-vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin*; *Antimicrobial Agents and Chemotherapy*; 1989, vol. 33, pp. 1783-1790.  
 Barry et al., *In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American Medical Centers*; *Antimicrobial Agents and Chemotherapy*; 2001, vol. 45, pp. 1919-1922.

(56)

## References Cited

## OTHER PUBLICATIONS

- Benvenuto et al., Pharmacokinetics and Tolerability of Daptomycin at Doses up to 12 Milligrams per Kilogram of Body Weight Once Daily in Healthy Volunteers; *Antimicrobial Agents and Chemotherapy*; 2006, vol. 50, pp. 3245-3249.
- Dvorchik et al., Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy Subjects; *Antimicrobial Agents and Chemotherapy*; 2003, vol. 47, pp. 1318-1323.
- Bingen et al., Bactericidal activity of Fancomycin, Daptomycin, Ampicillin and Aminoglycosides against Vancomycin-resistant Enterococcus; *J of Antimicrobial Chemotherapy*; 1990, vol. 26, pp. 619-626.
- Bryant et al., Effect of Abscess Milieu on Bactericidal Activity of IX146032 against *Staphylococci*; *Eur. J. Clin. Microbiol.*; 1987, vol. 6, pp. 186-188.
- Caballero\_Granado et al.; Case-control Study of Risk Factors for the Development of *Enterococcal bacteremia*; *Eur. J. Clin. Microbiol. Infect. Dis.* 2001, vol. 20, p. 83-90.
- Caron et al.; Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to highly glycopeptide-resistant isolate of *Enterococcus faecium*; *Antimicrobial Agents and Chemotherapy*; 1992, vol. 36, pp. 2611-2616.
- Carter et al., Protein Crystallization Using Incomplete Factorial Experiments; *J. Biol. Chem.*, 1979, vol. 254, pp. 12219-12223.
- Chaftari et al.; Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients; *International Journal of Antimicrobial Agents*; 2010, vol. 36, pp. 182-186.
- Chayen et al.; Recent advances in methodology for the crystallization of biological macromolecules; *Journal of Crystal Growth*; 1999, pp. 649-655.
- Crompton et al., Outcomes with daptomycin in the treatment of *Staphylococcus aureus* infections with a range of vancomycin Mics; *Journal of Antimicrobial Chemotherapy*; 2010, vol. 65, pp. 1784-1791.
- Cubicin label, Nov. 2011; 34 pages.
- Cui et al., Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate *Staphylococcus aureus*; *Antimicrobial Agents and Chemotherapy*; 2006, vol. 50, pp. 1079-1082.
- Cunha et al., Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant *Staphylococcus aureus* (MRSA) mitral valve acute bacterial endocarditis (ABE); *Eur. J. Clin. Microbiol. Infect. Dis.*; 2009, vol. 28, pp. 831-833.
- Davis et al., Daptomycin versus Vancomycin for Complicated Skin and Skin Structure Infections: Clinical and Economic Outcomes, *Pharmacotherapy*, 2007, vol. 27, pp. 1611-1618.
- Debbia et al., In Vitro Activity of LY146032 Alone and in Combination with Other Antibiotics against Gram-Positive Bacteria, *Antimicrobial Agents and Chemotherapy*, 1988, vol. 32, pp. 279-281.
- El-Mady et al., The Bactericidal Activity of Ampicillin, Daptomycin, and Vancomycin Against Ampicillin-Resistant *Enterococcus faecium*, *Diagn. Micro. Inf. Dis.*, 1991, vol. 14, pp. 141-145.
- Evdokimov et al., Overproduction, purification, crystallization and preliminary X-ray diffraction analysis of YopM, an essential virulence factor extruded by the plague bacterium *Yersinia pestis*, *Acta Crystallographica*, 2000, vol. 56, pp. 1676-1679.
- DuCruix, et al., Crystallization of Nucleic acids and Proteins, *A Practical Approach*, 2d ed., 1999, pp. 92-95, 4 pages.
- Forward et al., Comparative activity of daptomycin and teicoplanin against enterococci isolated from blood and urine, *Can. J. Infect. Dis.*, 1992, vol. 3, pp. 173-178.
- Fowler et al., Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by *Staphylococcus aureus*, *The New England Journal of Medicine*, 2006, vol. 355, pp. 653-665.
- Cubicin label.
- Amorij; Development of Stable Influenza Vaccine Powder Formulations: challenges and possibilities, *Pharmaceutical Research*, 2008, 25:1256-1273.
- Haworth et al.; *Staphylococcus aureus* ventriculitis treated with single-dose intraventricular vancomycin or daptomycin (LY146032): bacterial and antibiotic kinetics in hydrocephalic rabbits; *Antimicrobial Agents and Chemotherapy* 1990, vol. 34, pp. 245-251.
- Jancarik et al., Sparse matrix sampling: a screening method for crystallization of proteins, *J Appl. Cryst.*, 1991, vol. 24, pp. 409-411.
- Johnson et al., ICAA 1987, poster 161, 1 page.
- Katz et al., A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria, *International Journal of Clinical Practice*, 2008, pp. 1-10.
- LeClercq et al., Effects of Combinations of Beta-Lactams, Daptomycin, Gentamicin and Glycopeptides against Glycopeptide-Resistant Enterococci; *Antimicrobial Agents and Chemotherapy*, 1991, vol. 35, pp. 92-98.
- Louie et al., Comparison of in vitro inhibitory and Bactericidal Activities of Daptomycin (LY 146032) and Four Reference Antibiotics, Singly and in Combination, against Gentamicin-Susceptible and High-Level-Gentamicin-Resistant Enterococci; *Chemotherapy*; 1993, vol. 39, pp. 302-310.
- Luu et al., Treatment of Chronic Experimental *Staphylococcus aureus* Osteomyelitis with LY 146032 and Vancomycin; *Eur. J. Clin. Microbiol. Infect. Dis.* 1989, vol. 8, pp. 562-563.
- Mader et al., Comparative Evaluation of Daptomycin (LY146032) and comycin in the Treatment of Experimental Methicillin-Resistant *Staphylococcus aureus* Osteomyelitis in Rabbits; *Comparative Evaluation of Daptomycin Antimicrobial Agents and Chemotherapy*, 1989, vol. 33, pp. 689-692.
- Mariani et al., Development of decreased susceptibility to daptomycin and vancomycin in a *Staphylococcus aureus* strain during prolonged therapy; *Journal of Antimicrobial Chemotherapy* 2013, p. 481-83.
- Mathews et al., IDSA poster, 2001.
- Mchenney et al., Molecular Cloning and Physical Mapping of the Daptomycin Gene Cluster from *Streptomyces roseosporus*; *Journal of Bacteriology*, 1998, vol. 180, pp. 143-151.
- Mobarakai et al., Bactericidal Activities of Peptide Antibiotics against Multidrug-Resistant *Enterococcus faecium*; *Antimicrobial Agents and Chemotherapy*; 1994, vol. 38, pp. 385-387.
- Moise et al., Susceptibility relationship between vancomycin and daptomycin in *Staphylococcus aureus*: facts and assumptions; *Lancet Infect. Dis.* 2009, vol. 9, pp. 617-624.
- Patel et al., An Association between Reduced Susceptibility to Daptomycin and Reduced Susceptibility to Vancomycin in *Staphylococcus aureus*; *Clinical Infectious Diseases: Correspondence to the Editor*; Jun. 1, 2006, vol. 42, pp. 1652-1653.
- Sader et al., Nine-Hospital Study Comparing Broth Microdilution and Etest method Results for Vancomycin and Daptomycin against Methicillin-Resistant *Staphylococcus aureus*; *Antimicrobial Agents and Chemotherapy*, 2009, vol. 53, pp. 3162-3165.
- Sader et al., Update on the In Vitro Activity of Daptomycin Tested against 17,193 Gram-positive Bacteria Isolated from European Medical Centers (2005-2007); *Journal of Chemotherapy* 2009, vol. 21, pp. 500-506.
- Sakoulas et al., Clinical Outcomes of Patients Receiving Daptomycin for the Treatment of *Staphylococcus aureus* Infections and Assessment of Clinical Factors for Daptomycin Failure: A Retrospective Cohort Study Utilizing the Cubicin Outcomes Registry and Experience; *Clinical Therapeutics*, 2009, vol. 31, pp. 1936-1945.
- Sapico et al., 146032, Alone nad in Combination with Gentamicin, for the Treatment of *Enterococcal pyelonephritis* in the Rat Model; *Antimicrobial Agents and Chemotherapy* 1988, vol. 32, pp. 81-83.
- Silva et al., In Vitro Activity of LY146032 Against Gram-Positive Bacteria; *Diagn. Microbiol. Infect. Dis.*, 1988, vol. 9, pp. 79-85.
- Silverman et al., Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact; *The Journal of Infectious Disease*; 2005, vol. 191, pp. 2149-2152.
- Silverman et al., Resistance Studies with Daptomycin; *Antimicrobial Agents and Chemotherapy*; 2001, vol. 45, pp. 1799-1802.
- Snydman et al., Comparative In Vitro Activities of Daptomycin and Vancomycin against Resistant Gram-Positive Pathogens; *Antimicrobial Agents and Chemotherapy*; 2000, vol. 44, pp. 3447-3450.

(56)

## References Cited

## OTHER PUBLICATIONS

Steenbergen et al., Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections; *Journal of Antimicrobial Chemotherapy*, 2005, vol. 55, pp. 283-288.

Stratton et al., Bactericidal Activity of Daptomycin (LY146032) Compared with Those of Ciprofloxacin, Vancomycin, and Ampicillin against Enterococci as Determined by Kill-Kinetic Studies; *Antimicrobial Agents and Chemotherapy* 1987, vol. 31, pp. 1014-1016.

U.S. Appl. No. 10/024,405 (Abandoned).

Tenover et al., Characterisation of a *Staphylococcus aureus* strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy; *International Journal of Antimicrobial Agents*; 2009, p. 564-68.

Thibault et al., Attenuation by Daptomycin of Gentamicin-Induced Experimental Nephrotoxicity; *Antimicrobial Agents and Chemotherapy*; 1994, vol. 38, pp. 1027-1035.

Woodworth et al., Tobramycin and daptomycin disposition when co-administered to healthy volunteers; *Journal of Antimicrobial Chemotherapy*, 1994, vol. 33 pp. 655-659.

U.S. Appl. No. 61/243,402, filed Sep. 17, 2009 (Priority Document for WO2011035108).

U.S. Appl. No. 61/263,695, filed Nov. 23, 2009 (Priority Document for WO2011035108 and WO2011062676).

U.S. Appl. No. 61/371,802, filed Aug. 9, 2010 (Priority Document for WO2011062676).

*Cubist Pharmaceutical, Inc. v. Hospira, Inc.*, No. 1:12cv367 (D. Mass. Filed Mar. 21, 2012) (Def. Hospira, Inc. Preliminary Invalidation Contentions).

International Search Report and Written Opinion dated Aug. 22, 2011 in international application No. PCT/US2010/057910, 15 pgs.

Notification of Transmittal of International Preliminary Report on Patentability in International Application No. PCT/US2010/057910, mailed May 24, 2012, 7 pages.

Sun et al., "Development of an Improved Daptomycin Drug Product: Immediate Reconstitution, Room Temperature Product Stability and Reconstitution Stability", AAPS 2011, Abstract for Poster No. T3328  
Published Abstract: <http://abstracts.aaps.org/SecureView/AAPSJournal/vmqutdm9e488ov6bh0dy.pdf>.

Horowitz et al., Isolation and Characterization of a Surfactant Produced by *Bacillus licheniformis* 86; *Journal of Industrial Microbiology* 1990, vol. 6, pp. 243-248.

Fostel, et al., "Emerging Novel Antifungal Agents," *DDT*; vol. 5; No. 1; Jan. 2000; pp. 25-32.

Caballero Granado et al.; Case-control Study of Risk Factors for the Development of *Enterococcal bacteremia*; *Eur. J. Clin. Microbiol. Infect. Dis.* 2001, vol. 20, p. 83-90.

Desai et al., Microbial Production of Surfactants and Their Commercial Potential; *Microbiology and Molecular Biology Reviews* 1997, vol. 61, pp. 47-64.

Debruin, Michael F., Efficacy and safety of daptomycin for the treatment of bacteremia and serious infections due to gram-positive bacteria; 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections; Poster #594 P-S2-37 (Mar. 5-9, 2000), 14 pages.

Supplementary European Search Report PCT/US2010057910 Dated Feb. 28, 2014. 8 Pages.

Debono: Enzymatic and Chemical Modifications of Lipopeptide Antibiotic A21978C: The Synthesis and Evaluation of Daptomycin, *The Journal of Antibiotics*, 1988, 41(8):1093-1105.

\* cited by examiner



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.